A Phase 1, Open-label, Two-cohort, Single Dose Study to Assess the Mass Balance, Route of Elimination, and Metabolic Profile of [14C] Labeled CRN00808 and Absolute Bioavailability of CRN00808 in Healthy Male Volunteers
| Registry | NCT04246749 |
|---|---|
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional; non randomized, single group, masking: none, treatment |
| Enrollment | 11 (Actual) |
| Sponsor | Crinetics Pharmaceuticals Inc. (Industry) |
| Conditions | Healthy Volunteers |
| Interventions | [14C]-CRN00808, CRN00808 (Drug) |
| Dates | start 2019-09-17, primary completion 2019-10-25, completion 2019-10-25, first posted 2020-01-29, last updated 2020-01-29 |
| Locations | 1 site in Netherlands |
Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Healthy Volunteers All trials of [14C]-CRN00808 All trials of CRN00808
A phase 1 healthy volunteer study to assess the mass balance, elimination, and metabolic profile of CRN00808. The study will be conducted in 2 parts: Part A, to characterize the absorption, distribution, metabolism, excretion, and mass balance of orally administered radio-labeled CRN00808; Part B, to determine the absolute bioavailability of CRN00808 administered using CRN00808 and radio-labeled CRN00808 as intravenous and oral forms.
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Part A: [14C]-CRN00808 Oral Solution | Experimental | Drug: [14C]-CRN00808 | Single oral dose of CRN00808 containing \[14C\]-CRN00808 |
| Part B: CRN00808 Oral Capsule w/ [14C]-CRN00808 IV microtracer | Experimental | Drug: [14C]-CRN00808; Drug: CRN00808 | Single oral dose of CRN00808 followed by \[14C\]-CRN00808 IV microtracer injection |
Sex: Male, ages: 19 Years to 55 Years, accepts healthy volunteers
Inclusion Criteria: 1. Male subjects 19 to 55 years of age 2. BMI 18 to 30 kg/m2 Exclusion Criteria: 1. Any uncontrolled or active major systemic disease including, but not limited to: acromegaly (with or without pituitary surgery or radiation therapy), cardiac, pulmonary, gastrointestinal, metabolic, urogenital, neurological, immunological, psychiatric, or neoplastic disorder with metastatic potential 2. History or presence of malignancy within the past 5 years. Subjects who have been successfully treated (for 3 months or longer) with no recurrence of basal or squamous cell carcinoma of the skin or carcinoma in-situ of the cervix may be enrolled. 3. Use of any investigational drug within the past 60 days or 5 half-lives, whichever is longer 4. Have a medically significant abnormality observed during screening or the admission physical examination or in any other baseline measurements 5. Use of any prior medication without approval of the investigator within 14 days prior to admission 6. Tested positive at screening for HIV, hepatitis B surface antigen (HBsAg) or hepatitis C antibody (HCV-Ab) or has a history of a positive result 7. History of alcohol or substance abuse in the past 6 months 8. Any condition that in the opinion of the investigator would jeopardize the subject's appropriate participation in this Phase 1 study
| Facility | City | Country | Status |
|---|---|---|---|
| PRA Health Sciences | Groningen | Netherlands |